The funding will support further commercialization efforts of the company’s flagship product, the Accuryn Monitoring System.
Potrero Medical, Inc., a predictive health company focused on using smart sensors and analytics for early detection of critical illnesses, recently announced the closing of a $26.6 million Series C financing. The financing was led by China-focused healthcare investment firm GT Healthcare Capital Partners and Silicon Valley-based Sonder Capital. The funding will support further commercialization efforts of the company’s flagship product, the Accuryn Monitoring System.
With the Accuryn Monitoring System, Potrero Medical is transforming critical care monitoring by evolving the traditional urinary catheter into a smart sensor that helps to accurately monitor patients’ vital signs in real-time. The technology is the world’s first commercially available system for ICU patients that can fully integrate physiological measurements for intra-abdominal pressure, urine output, and core body temperature.
The capital Potrero Medical raised will also be used in developing an artificial intelligence platform to assist physicians with early intervention of life threatening events, such as Acute Kidney Injury (AKI).